You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Azurity Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Azurity

Drugs and US Patents for Azurity

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Azurity EDARBYCLOR azilsartan kamedoxomil; chlorthalidone TABLET;ORAL 202331-001 Dec 20, 2011 RX Yes No 9,169,238 ⤷  Subscribe Y ⤷  Subscribe
Azurity EVEKEO ODT amphetamine sulfate TABLET, ORALLY DISINTEGRATING;ORAL 209905-005 Apr 16, 2021 DISCN Yes No 11,160,772 ⤷  Subscribe Y ⤷  Subscribe
Azurity FIRVANQ KIT vancomycin hydrochloride FOR SOLUTION;ORAL 208910-002 Jan 26, 2018 AB RX Yes Yes 10,959,949 ⤷  Subscribe Y ⤷  Subscribe
Azurity HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-002 Dec 13, 2011 RX Yes No 8,114,909 ⤷  Subscribe ⤷  Subscribe
Azurity HORIZANT gabapentin enacarbil TABLET, EXTENDED RELEASE;ORAL 022399-001 Apr 6, 2011 RX Yes Yes 8,114,909 ⤷  Subscribe ⤷  Subscribe
Azurity THYQUIDITY levothyroxine sodium SOLUTION;ORAL 214047-001 Nov 30, 2020 RX Yes Yes 9,050,307 ⤷  Subscribe Y ⤷  Subscribe
Azurity TRIPTODUR KIT triptorelin pamoate FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 208956-001 Jun 29, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 7 of 7 entries

Expired US Patents for Azurity

ApplicantTradenameGeneric NameDosageNDAApproval DatePatent No.Patent Expiration
Azurity EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-001 Feb 25, 2011 5,736,555 ⤷  Subscribe
Azurity EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-002 Feb 25, 2011 5,736,555 ⤷  Subscribe
Azurity EDARBI azilsartan kamedoxomil TABLET;ORAL 200796-001 Feb 25, 2011 7,572,920 ⤷  Subscribe
Azurity EVEKEO ODT amphetamine sulfate TABLET, ORALLY DISINTEGRATING;ORAL 209905-002 Jan 30, 2019 10,130,580 ⤷  Subscribe
Azurity GLIADEL carmustine IMPLANT;INTRACRANIAL 020637-001 Sep 23, 1996 5,179,189 ⤷  Subscribe
Azurity NYMALIZE nimodipine SOLUTION;ORAL 203340-002 Apr 8, 2020 8,517,997 ⤷  Subscribe
Azurity VERELAN verapamil hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 019614-001 May 29, 1990 4,863,742 ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>Patent No.>Patent Expiration
Showing 1 to 7 of 7 entries
Paragraph IV (Patent) Challenges for AZURITY drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 300 mg ➤ Subscribe 2006-05-19
➤ Subscribe Oral Solution 1 mg/mL ➤ Subscribe 2018-08-31
➤ Subscribe Extended-release Tablets 100 mg and 200 mg ➤ Subscribe 2006-07-20
➤ Subscribe Powder for Oral Solution 1 mg/mL ➤ Subscribe 2016-06-21

International Patents for Azurity Drugs

CountryPatent NumberEstimated Expiration
Canada 2538802 ⤷  Subscribe
China 106573037 ⤷  Subscribe
Cyprus 1113583 ⤷  Subscribe
Norway 338275 ⤷  Subscribe
Norway 20083956 ⤷  Subscribe
South Africa 200309679 ⤷  Subscribe
South Korea 20070017977 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration
Showing 1 to 7 of 7 entries

Supplementary Protection Certificates for Azurity Drugs

Patent NumberSupplementary Protection CertificateSPC CountrySPC ExpirationSPC Description
1003503 05C0048 France ⤷  Subscribe PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
1718641 1290016-3 Sweden ⤷  Subscribe PRODUCT NAME: AZILSARTANMEDOXOMIL OCH FARMACEUTISKT GODTAGBARA SALTER DAERAV, INKLUDERANDE KALIUMSALT; REG. NO/DATE: EU/1/11/735/001 20111207
2119715 2018/006 Ireland ⤷  Subscribe PRODUCT NAME: COMBINATION OF AZILSARTAN MEDOXOMIL AND CHLORTALIDONE (EDARBYCLOR); NAT REGISTRATION NO/DATE: PA/2167/001/001-002 20170804; FIRST REGISTRATION NO/DATE: 63145 01-02 20141028
1718641 436 Finland ⤷  Subscribe
0503785 CA 2011 00026 Denmark ⤷  Subscribe PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
1718641 PA2012004,C1718641 Lithuania ⤷  Subscribe PRODUCT NAME: AZILSARTANUM MEDOXOMILUM; REGISTRATION NO/DATE: EU/1/11/734/001 - EU/1/11/734/011, 2011 12 07, EU/1/11/735/001 - EU/1/11/735/011 20111207
0984957 SPC/GB11/013 United Kingdom ⤷  Subscribe PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
>Patent Number>Supplementary Protection Certificate>SPC Country>SPC Expiration>SPC Description
Showing 1 to 7 of 7 entries
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.